Respiratory

Back to articles

Varenicline for smoking cessation

KEY POINT

Results of a clinical trial and a systematic review of varenicline (Chantix—Pfizer) confirm its safety and efficacy for smoking cessation in doses of 1 mg twice daily for up to 52 weeks.

SOURCES

Williams K et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23:793–801.

Cahill K et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD006103.

Chantix [package insert]. New York, NY: Pfizer; 2007.